This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message >> Message Archive (October 30, 2017)

PRINT

To Our Investors

I would like to express my sincere appreciation to all shareholders who support Japan Tissue Engineering (J-TEC). I will report below the company’s most recent developments.

Review of the First Half of FY2017

Aiichiro Hiruma
President & CEO Aiichiro Hiruma

We achieved profitability in FY2016 for the first time since the company’s establishment, and we continue to strive towards the goal of further growth this year.
We released the summary of financial results for the 2nd Quarter of FY2017 today, and I would like to review the first half. In this first half, sales of Autologous Cultured Epidermis JACE increased considerably as we received an additional indication approval for Giant Nevus in Japan. JACE is rapidly achieving widespread use for Giant Nevus treatment in Japan since its approval in December 2016. So far, 18 medical institutions have already performed this treatment.
On the other hand, despite the increasing number of hospitals certified to use Autologous Cultured Cartilage JACC, the sales recorded only a slight growth, as we could not pile additional orders from new medical institutions.
Overall, the total sales increased by 42% compared to the same period last year. In an effort to leap forward, we will continue to work hard for further expansion.


A new business segment

From this fiscal year, in addition to the "Regenerative Medicine Business" and "R&D Support Business", we have added “Custom Development and Manufacturing Business” as a new segment to our core business.
In July 2017, Nagoya City University Hospital started the clinical research using cultured epidermis to treat vitiligo patients and they have outsourced the production of cultured epidermis to J-TEC, providing a new option for vitiligo treatment. In addition to medical institutions, we have also acquired new contract development and manufacturing orders from several companies, academia and research organizations.

We will make full use of our accumulated know-how, and aim to expand sales and make developments that lead to our further growth. I sincerely hope to have your continuous support.

October 30, 2017
Aiichiro Hiruma
President & CEO
Japan Tissue Engineering Co., Ltd.